ArticleCancer chemotherapy and pharmacology2022

Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Bei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.